News Feed
Description:

http://www.diabetesincontrol.com/articles/diabetes-news/18347-new-triglyceride-lowering-drug

Post date: Tuesday, September 8, 2015 - 14:15
Nid: 608
Image:
Name: Andi
Description:

In a presentation at the American Diabetes Association’s 2015 Scientific Sessions, Dianne Fetchick, MD and Rosemarie Lajara, MD, endocrinologists with Diabetes America in Plano, TX, shared results of their use of the V-Go insulin pump with their patients.  The V-Go pump is a small 2.4 x 1.3 x 0.5-inch disposable manual insulin delivery device.  The device delivers 20, 30, or 40 units of basal insulin evenly over a 24-hour period, and the wearer can deliver mealtime bolus insulin in two units per click increments.

 

For individuals who are unwilling to give themselves multiple daily injections, this may be an alternative. Two studies were reported at the meeting: 72 patients—most of whom had Type 2 diabetes—had been switched from multiple daily injections (39); basal insulin only (24); or oral glucose-lowering medications (9).  The analysis of their electronic medical record showed a decrease in A1C levels.  At baseline, A1C levels were on average 9.6% at 88 days.  A1C decreased to 7.9% at 177 days—a decrease of 7.6%, and at 279 days—7.7%.  Patients who had been on basal insulin alone or noninsulin agents had the greatest reduction in A1C—1.9 and 3.5 percentage points from their baselines of 9.8% and 10.9%.  Patients who had already been taking insulin who used the V-Go reduced their total insulin usage by 20.5%.

Post date: Tuesday, September 8, 2015 - 14:11
Nid: 607
Image:
Name: Andi
Description:

http://www.endocrinologyadvisor.com/bone-metabolism/osteoporosis-vitamin-d-bone-mineral-density-postmenopausal-women/article/430520/

Post date: Tuesday, September 8, 2015 - 14:06
Nid: 606
Image:
Name: Andi
Description:

http://www.npr.org/sections/health-shots/2015/08/26/434892642/texting-helps-diabetes-patients-fine-tune-insulin-dosing

Post date: Tuesday, September 8, 2015 - 14:04
Nid: 605
Image:
Name: Andi
Description:

The Diabetes Research Institute (DRI) at the University of Miami has received approval from the Food and Drug Administration to perform Phase I/II clinical trials to test using the omentum (the inside lining of the abdomen) as a new transplant site.  Presently islet cells are placed near the liver.  These trials will determine if the omentum is a better home for islet cells than the liver.  The research team, led by Dr. Rodolfo Alejandro, has screened hundreds of patients and is now waiting for matching organs to extract islet cells.

 

The team has also created a biodegradable scaffold consisting of the patient’s own plasma and clinical-grade thrombin – a BioHub platform.   Researchers will evaluate the two transplant sites by using the same anti-rejection drug therapy; however, DRI hopes in the future to totally eliminate the need for immunosuppression medication.  Researchers will evaluate whether the severe hypoglycemia has ceased and if the recipient is able to maintain an A1C of ≤ 6.5%.

Post date: Tuesday, August 4, 2015 - 21:39
Nid: 604
Image:
Name: Andi
Description:

Researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women’s College Hospital in Toronto, Canada are studying women with diabetes and their risk of breast cancer.  Their findings indicate that women with diabetes may be predisposed to a more advanced stage of breast cancer and, therefore, this may be a contributing factor in women with diabetes’ higher cancer mortality.  Based on these findings, it may be necessary to adjust breast cancer screening and detection methods in this population.  

 

Researchers analyzed data from more than 38,000 women between the ages of 20 - 105 who were diagnosed with invasive breast cancer between 2007– 2012.  Approximately 16% had diabetes.  Women with diabetes were 14% more likely to have Stage II breast cancer, 21% more likely to have Stage III breast cancer, and 16% more likely to have stage IV breast cancer—as compared to having Stage I, which is more treatable.

 

Five-year survival rates of women with diabetes and breast cancer were 15% lower than for women without diabetes.  Also, women with diabetes were more likely to have larger tumors and cancer that had spread to other areas.

Interestingly, women with diabetes reported lower mammogram rates.  Further research is needed and it is important that women not only manage their diabetes but that they also be sure to follow other preventive health measures.

Post date: Tuesday, August 4, 2015 - 21:33
Nid: 603
Image:
Name: Andi
Description:

The Food and Drug Administration recently approved Toujeo®, a new long-acting insulin developed by Sanofi.  Sanofi hopes that Toujeo will replace Lantus, their current long-acting insulin, which is due to lose its patent protection in the United States in a little over two years—allowing other pharmaceutical companies to develop a generic form of Lantus. 

Toujeo still uses the active ingredient glargine, which is used in Lantus—but at three times the concentration, and it’s designed to release insulin more gradually.  Toujeo provides similar blood glucose control as Lantus but with fewer episodes of hypoglycemia.  Toujeo will be available in a Solostar pen that will contain 450 units of Toujeo, but will require one-third less injection volume as compared to Lantus.  This insulin will be especially helpful for individuals who have insulin resistance and require a large volume of insulin to lower their blood glucose levels. 

Post date: Tuesday, August 4, 2015 - 21:30
Nid: 602
Image:
Name: Andi
Description:

Let’s keep it simple; 5-2-1-0 Let’s Go! is a nationally recognized childhood obesity prevention program with a simple message: Live a healthy lifestyle by eating healthy, exercising, eliminating sugary drinks, and limiting time on gadgets (iPhone, computer, TV, etc.).  It’s a program aimed at fighting childhood obesity; however, it is a program that everyone should adopt… young and old alike can all benefit from the program’s message.

These are the steps in a nutshell:

5 – or more fruits and vegetables each day.  A diet that has lots of fruits and vegetables lowers the risk of chronic disease and prevents weight gain.

2 – hours or less of recreational screen time (TV and computer).  According to the Academy of Pediatrics children spend an average of seven hours a day watching TV, playing on the computer, various phones, or other electronic devices.  Reducing screen time will have a significant impact on a child’s health.

1 – hour or more of physical activity daily. Physical activity has endless benefits including improving mood, boosting energy, improving sleep, helping to prevent chronic disease, and controlling weight.  We all need to become more physically active.

0 – sugary drinks, more water and low-fat milk.  Eliminate sugary drinks such as soda, juice and sports drinks.  These drinks are associated with lots of calories = weight gain and tooth decay. Drink water instead.

Encourage your family and friends to adopt the 5-2-1-0 Let’s Go! program and get healthy.  

 

Post date: Tuesday, August 4, 2015 - 21:20
Nid: 600
Image:
Name: Andi
Description:

Wouldn’t it be wonderful if the insulin injected was able to decide when it was needed?  What if it were essentially able to turn itself on and off?  Well, researchers are looking at just that ability. A team of researchers at the University of Utah and Massachusetts Institute of Technology are working on a new form of insulin that is glucose responsive.  This would allow insulin to be self-regulating.  Researchers are trying a new approach using a chemical group known as PBA.  PBA would bind to the glucose and activate the insulin whenever it is needed.  In mouse models Ins-PBA-F works as quickly as insulin does in a healthy mouse.  Researchers hope to reach clinical trials in two to five years.  

Post date: Tuesday, August 4, 2015 - 21:18
Nid: 599
Image:
Name: Andi
Description:

The new Apple Watch is able to use an app that can monitor blood glucose levels.  The app was designed by DexCom and can track and display glucose levels in the form of a graph.   DexCom’s glucose monitor will take the form of a body sensor that you wear around your abdomen. The body sensor measures your blood glucose levels every five minutes and sends the information to a remote handheld device within 20 feet.  This device is then able to communicate with the iPhone, which then sends the data to the Apple Watch to be displayed.  The advantage is that you can just look at your watch rather than having to check your iPhone or DexCom’s remote handheld device.  DexCom offers two apps through their Share System; one is installed on the user’s device allowing the data to be viewed by the user; the second app is installed on another person’s device with whom the user wants to share the data—perhaps a doctor or a caregiver.  

Post date: Tuesday, August 4, 2015 - 21:17
Nid: 598
Image:
Name: Andi

Pages